Characteristics | Normal | Slow | All | Uni-variable p-value | Multi-variable p-value |
---|---|---|---|---|---|
N | 188 | 14 | 202 | ||
Sex, males (%) | 136(72) | 11(79) | 147(73) | n.s.‡ | |
Age, y* | 69.1(± 10.8) (36–89) | 73.4(± 13.2) (48–93) | 69.4(± 11.0) (36–93) | 0.16 | 0.49 |
BMI* | 29.2(± 5.5) (17.1–55.1) | 29.0(± 4.3) (22.2–40.1) | 29.2(± 5.4) (17.1–55.1) | n.s | |
Weekly warfarin dose, mg* | 29.7(± 12.3) (6.25–77) | 23.2(± 13.7) (8.75–57.5) | 29.3(± 12.4) (6.25–77) | 0.06 | 0.20 |
Baseline INR* | 2.6(± 0.5) (2.0–4.2) | 3.2(± 0.6) (2.1–4.3) | 2.7(± 0.5) (2.0–4.3) | 0.0004 | 0.0021 |
Day of last dose warfarin* (in relation to surgery) | -6.1(± 0.5) (-8 – -5) | -6.1(± 0.3) (-7 – -6) | -6.1(± 0.5) | n.s. | |
Pre-operative creatinine, μmol/L* | 104(± 34) (49–336) | 120(± 41) (65–196) | 105(± 35) (49–336) | 0.09 | 0.40 |
Known liver disease (%) | 7(3.7) | 1(7.1) | 8(4.0) | n.s. | |
Medication interaction score* | 1.5(± 1.3) (-1 – 5) | 1.4(± 1.4) (0–4) | 1.5(± 1.3) (-1 – 5) | n.s. | |
Number of concomitant drugs* | 7 (± 3) (0–14) | 8 (± 3) (4–16) | 7 (± 3) (0–16) | n.s. | |
Amiodarone medication (%) | 29(15) | 2(14) | 31(15) | n.s. | |
Thyroid hormone treatment (%) | 21(11) | 2(14) | 23(11) | n.s. |